QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
GE   79.81 (-0.15%)
F   16.32 (+0.87%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
GE   79.81 (-0.15%)
F   16.32 (+0.87%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
GE   79.81 (-0.15%)
F   16.32 (+0.87%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
GE   79.81 (-0.15%)
F   16.32 (+0.87%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
NASDAQ:REGN

Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News

$643.29
+14.58 (+2.32%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$624.81
$643.71
50-Day Range
$548.35
$643.29
52-Week Range
$538.01
$747.42
Volume
541,026 shs
Average Volume
689,625 shs
Market Capitalization
$70.12 billion
P/E Ratio
12.84
Dividend Yield
N/A
Price Target
$698.35

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
8.6% Upside
$698.35 Price Target
Short Interest
Bearish
2.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
-0.04mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$31.66 M Sold Last Quarter
Proj. Earnings Growth
6.80%
From $35.90 to $38.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

283rd out of 1,125 stocks

Pharmaceutical Preparations Industry

134th out of 554 stocks

REGN stock logo

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded up $0.65 during mid-day trading on Monday, reaching $629.36. 3,887 shares of the company's stock were exchanged, compared to its average volume of 690,586. Regeneron Pharmaceuticals has a one year low of $538.01 and a one year high of $747.42. The firm has a market capitalization of $68.61 billion, a PE ratio of 12.55, a price-to-earnings-growth ratio of 2.19 and a beta of 0.29. The business's fifty day simple moving average is $595.86 and its two-hundred day simple moving average is $636.87. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.39 and a current ratio of 5.12.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Rating) last posted its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 earnings per share for the quarter, missing analysts' consensus estimates of $9.94 by ($0.17). Regeneron Pharmaceuticals had a net margin of 39.97% and a return on equity of 36.17%. The company had revenue of $2.86 billion during the quarter, compared to analyst estimates of $2.80 billion. During the same quarter in the previous year, the business posted $27.97 earnings per share. The company's revenue for the quarter was down 44.4% on a year-over-year basis. Analysts anticipate that Regeneron Pharmaceuticals will post 35.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on REGN shares. Wells Fargo & Company reduced their price target on Regeneron Pharmaceuticals from $750.00 to $735.00 and set an "overweight" rating for the company in a research report on Friday, June 3rd. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, July 12th. They issued a "neutral" rating and a $625.00 price target for the company. BMO Capital Markets raised their target price on Regeneron Pharmaceuticals from $757.00 to $788.00 and gave the stock an "outperform" rating in a research note on Thursday, August 4th. StockNews.com lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, July 26th. Finally, Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $619.00 to $625.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 4th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $698.35.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $620.91, for a total transaction of $9,313,650.00. Following the completion of the transaction, the director now owns 1,872 shares in the company, valued at approximately $1,162,343.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Christine A. Poon sold 15,000 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $620.91, for a total value of $9,313,650.00. Following the completion of the sale, the director now owns 1,872 shares in the company, valued at approximately $1,162,343.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 1,100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, July 1st. The shares were sold at an average price of $587.76, for a total transaction of $646,536.00. Following the completion of the sale, the executive vice president now owns 19,644 shares of the company's stock, valued at approximately $11,545,957.44. The disclosure for this sale can be found here. In the last 90 days, insiders sold 51,435 shares of company stock worth $31,663,304. 8.99% of the stock is currently owned by insiders.

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Stock News Headlines

Regeneron's 'Regeneration' May Not Last Long
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings
8/03/2022
Today
8/15/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
10,368
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$698.35
High Stock Price Forecast
$844.00
Low Stock Price Forecast
$536.00
Forecasted Upside/Downside
+8.6%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
19 Analysts

Profitability

Net Income
$8.08 billion
Pretax Margin
44.59%

Debt

Sales & Book Value

Annual Sales
$16.07 billion
Cash Flow
$82.69 per share
Book Value
$172.92 per share

Miscellaneous

Free Float
99,208,000
Market Cap
$70.12 billion
Optionable
Optionable
Beta
0.29

Social Links















REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" REGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in REGN, but not buy additional shares or sell existing shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price forecast for 2022?

19 brokerages have issued 1-year price objectives for Regeneron Pharmaceuticals' stock. Their REGN share price forecasts range from $536.00 to $844.00. On average, they predict the company's share price to reach $698.35 in the next year. This suggests a possible upside of 8.6% from the stock's current price.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2022?

Regeneron Pharmaceuticals' stock was trading at $631.52 on January 1st, 2022. Since then, REGN stock has increased by 1.9% and is now trading at $643.29.
View the best growth stocks for 2022 here
.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our REGN earnings forecast
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its quarterly earnings results on Wednesday, August, 3rd. The biopharmaceutical company reported $9.77 earnings per share (EPS) for the quarter, missing the consensus estimate of $9.94 by $0.17. The biopharmaceutical company earned $2.86 billion during the quarter, compared to analyst estimates of $2.80 billion. Regeneron Pharmaceuticals had a net margin of 39.97% and a trailing twelve-month return on equity of 36.17%. Regeneron Pharmaceuticals's revenue was down 44.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $27.97 EPS.
Read the conference call transcript
.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (9.34%), Dodge & Cox (2.09%), Loomis Sayles & Co. L P (1.63%), Northern Trust Corp (1.10%), California Public Employees Retirement System (0.71%) and UBS Asset Management Americas Inc. (0.55%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry, Robert E Landry and Sanofi.
View institutional ownership trends
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $643.29.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $70.12 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $50.10 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

The company employs 10,368 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
When was Regeneron Pharmaceuticals founded?

Regeneron Pharmaceuticals was founded in 1988.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.